Literature DB >> 28667822

Effects of comorbid substance use disorders on outcomes in a Housing First intervention for homeless people with mental illness.

Karen Urbanoski1, Scott Veldhuizen2, Michael Krausz3, Christian Schutz3, Julian M Somers4, Maritt Kirst5, Marie-Josée Fleury6, Vicky Stergiopoulos7, Michelle Patterson3, Verena Strehlau3, Paula Goering7.   

Abstract

BACKGROUND AND AIMS: Evidence supports the effectiveness of Housing First (HF) programmes for people who are experiencing homelessness and mental illness; however, questions remain about its use in people with comorbid substance use disorders (SUD). The aim of this project was to test whether SUD modifies the effectiveness of an HF intervention.
DESIGN: Secondary analysis of data from a randomized controlled trial of HF versus treatment-as-usual (TAU) with 24-month follow-up, comparing those with and without SUD at trial entry.
SETTING: Vancouver, Toronto, Winnipeg, Moncton and Montreal, Canada. PARTICIPANTS: A total of 2154 participants recruited from 2009 to 2013 and randomized to HF versus TAU (67% male, mean age 40.8 ± 11.2, 25% ethno-cultural minority). All were homeless and had a mental disorder at baseline; 35% reported symptoms consistent with SUD. INTERVENTION: Housing paired with Intensive Case Management or Assertive Community Treatment. MEASUREMENTS: Primary outcomes were days housed and community functioning. Secondary outcomes were general and health-related quality of life and mental health symptoms. Predictors were SUD status crossed with intervention group (HF versus TAU).
FINDINGS: People with SUD in both the HF and TAU groups spent less time in stable housing, but the effect of HF did not vary by SUD status [odds ratio (OR) = 1.17, 95% confidence interval (CI) = -0.77, 1.76]. Similarly, there was no difference between those with and without SUD in the effect of HF (over TAU) on community functioning (b = 0.75, 95% CI = -0.36, 1.87), quality of life (b = -1.27, 95% CI = -4.17, 1.63), health-related quality of life (b = -0.01, 95% CI = -0.03, 0.02) or mental health symptoms (b = 0.43, 95% CI = -0.99, 1.86).
CONCLUSIONS: Housing First programs in Canada are equally effective in people with and without comorbid substance use disorder (SUD). Overall, the intervention appears to be able to engage people with SUD and is reasonably successful at housing them, without housing being contingent upon abstinence or treatment.
© 2017 Society for the Study of Addiction.

Entities:  

Keywords:  Comorbidity; homelessness; housing first; mental illness; randomized controlled trial; substance use disorders

Mesh:

Year:  2017        PMID: 28667822     DOI: 10.1111/add.13928

Source DB:  PubMed          Journal:  Addiction        ISSN: 0965-2140            Impact factor:   6.526


  5 in total

1.  Associations of alcohol use disorder, alcohol use, housing, and service use in a homeless sample of 255 individuals followed over 2 years.

Authors:  Olubunmi O Asana; Emine R Ayvaci; David E Pollio; Barry A Hong; Carol S North
Journal:  Subst Abus       Date:  2018-10-31       Impact factor: 3.716

2.  A Place to Call Home: Hearing the Perspectives of People Living with Homelessness and Mental Illness Through Service Evaluation.

Authors:  Julie O'Donovan; Karen Russell; Pim Kuipers; Dan Siskind; Rachel A Elphinston
Journal:  Community Ment Health J       Date:  2019-05-16

3.  Comorbidity profiles of patients experiencing homelessness: A latent class analysis.

Authors:  Keshab Subedi; Shweta Ghimire
Journal:  PLoS One       Date:  2022-05-24       Impact factor: 3.752

4.  Social networks and substance use after transitioning into permanentsupportive housing.

Authors:  Harmony Rhoades; Wichada La Motte-Kerr; Lei Duan; Darlene Woo; Eric Rice; Benjamin Henwood; Taylor Harris; Suzanne L Wenzel
Journal:  Drug Alcohol Depend       Date:  2018-07-29       Impact factor: 4.492

5.  Editorial: Community-Based Outreach Treatment for Addictions and Concomitant Disorders: Time for a Change of Paradigm.

Authors:  Louise Penzenstadler; Yasser Khazaal; Marie-Josée Fleury
Journal:  Front Psychiatry       Date:  2020-01-22       Impact factor: 4.157

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.